Sergey Terushkin, MD, FACS Key Takeaways: Mounjaro (tirzepatide) targets GIP + GLP-1 receptors , while Ozempic (semaglutide) targets GLP-1 only Clinical studies show greater average weight loss with tirzepatide in many patients Both medications require BMI 30 or 27 with weight-related conditions Common side effects include nausea, GI discomfort, and appetite changes , usually improving with dose adjustment Insurance coverage varies more common for diabetes than weight loss Prescription required treatment must be doctor-guided and medically supervised If you are deciding between Mounjaro and Ozempic for weight loss in 2026, the key difference is that tirzepatide (Mounjaro) activates two metabolic pathways (GIP + GLP-1), while semaglutide (Ozempic) activates one (GLP-1) which may impact weight loss outcomes and tolerability
With new 2026 guidelines endorsing their use in high-risk patients, its time to look closely at how to identify liver-first candidates, select the most effective incretin therapies, and track both hepatic and cardiometabolic progress
We offer private, comfortable rooms where you can relax during your visit
Avoid risky behaviors Be sure to use barrier protection (condoms) when having sex
TB500 is not approved by the FDA for human use and is for research purposes only
